Eltrombopag use in adults with primary ITP: real-world patterns and outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study analyzes real-world treatment patterns and clinical outcomes for eltrombopag in adults with primary immune thrombocytopenia who have received prior corticosteroids. Data come from secondary sources provided by health care professionals across the US, UK, and Germany, plus a structured HCP survey collecting primary information. The study involves abstracting patient-chart data and gathering survey responses from eligible hematologists and related specialists. No experimental interventions are planned; the focus is on describing current practice and outcomes in routine clinical care. Eligibility requires experienced HCPs actively managing adult primary ITP and meeting minimum patient-volume criteria, with patient inclusion based on confirmed primary ITP diagnosis.

Why it matters

Who can join: the full rules

Inclusion criteria:

HCP inclusion criteria:

1. A licensed HCP (e.g., internal medicine specialist, hematologist, hematologist-oncologist or immunologist etc.) involved in the management of adult patients with primary ITP.
2. Actively involved in treatment decision-making for primary ITP patients at the time of the study.
3. Have a minimum of 3 years of experience managing patients with primary ITP.
4. Currently, managing an average of at least 2 adult primary ITP patients per month, including those treated with eltrombopag.
5. Able and willing to complete a web-based survey (approximately 60 to 70 minutes) and abstract data from 2 eligible patient charts.
6. Practicing in one of the study countries (US, UK, or Germany).
7. Have access to a computer or mobile device with internet connectivity to complete the survey.
8. Not listed as inactive or retired in the panel database.

Patient-level inclusion criteria:

1. Confirmed diagnosis of primary ITP.
2. Aged ≥18 years at the time of diagnosis.
3. Received first-line corticosteroid therapy (with or without intravenous immune globulin \[IVIg\]).
4. Initiated eltrombopag treatment (with or without corticosteroids) as first non-steroidal ITP treatment between 01 January 2020 and 31 December 2024.
5. Have at least 6 months of follow-up data available after the index date (unless deceased within that period).

Exclusion criteria:

HCP exclusion criteria:

1. Currently employed by a pharmaceutical company or regulatory authority involved in the approval or marketing of treatments for primary ITP.
2. Unable to provide data for patients who meet the study's inclusion criteria.
3. Not currently managing patients with primary ITP or are not involved in treatment decisions for these patients.

Patient-level exclusion criteria:

1\. Diagnosis of Evans syndrome, secondary ITP, or non-immune thrombocytopenia.

Where it's running

• Novartis
  Basel, Switzerland Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

• GL-2045 safety and blood-count help for adults with ITP

  GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.

  Recruiting Phase 1 Gliknik Inc. · Leeds · NCT07605845

• Daratumumab versus rituximab for children with primary immune thrombocytopenia

  This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07362238

• Daratumumab plus rituximab for adults with relapsed or refractory immune thrombocytopenia

  This treatment combines daratumumab (an anti‑CD38 antibody) with rituximab to see if it raises platelet counts in adults with ITP who haven't responded to steroids and other therapies.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07362199

• Daratumumab versus rituximab for adult primary immune thrombocytopenia

  This trial will test whether daratumumab (an anti‑CD38 antibody) works better than rituximab for adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07297563

• Rituximab plus anti‑CD38 antibody versus rituximab alone for primary immune thrombocytopenia

  This trial will test whether adding an anti‑CD38 antibody (daratumumab) to rituximab helps adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07234019

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.